12,372 trials
Atrial Fibrillation · Stroke
Primary: Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death — 2.2; 3.7 events per 100 pt yrs
Major Depressive Disorder
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 49; 2 Participants
Influenza
Primary: Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains). — 6.7; 15.8 percentage of participants — p=<0.0001
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal IOP (Intraocular Pressure) at End of Study — -3.2; -1.7 mmHg — p=< 0.001
Rheumatoid Arthritis
Primary: Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24 — 73.23 percentage of participants
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of Study — -2.6; -0.9; -2.2 mmHg — p=< 0.001
Atrial Fibrillation
Primary: Incidence of Postoperative Atrial Fibrillation — 5; 4; 5 participants
Anemia
Primary: Incidence of Treatment-emergent Serious Adverse Events (SAE's) — 11; 36 participants
Mucopolysaccharidosis II
Primary: Ranked Adjusted 2-Component Composite Variable Score Based on Change From Baseline to Week 53 — 69.81; 50.86 sum of the ranked scores — p=0.0049
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
Major Depressive Disorder
Primary: Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score — -6.18; -6.25; -6.91 units on a scale — p=0.264
Osteoarthritis
Primary: Safety of Meloxicam 10 mg as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination — 406; 23; 35; 127 participants
Musculoskeletal Complications · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Area Under Curve (AUC) of Average Pain From Diary vs. Day (1-5), Calculated by the Trapezoidal Rule. — 6.04; 7.71 (Pain Scale Score)*Days — p=0.037